Saman Rahmanian is a co-founder of Ro and its Chief Product Officer. The other co-founders are Zachariah Reitano, the CEO, and Rob Schutz, the Chief Growth Officer.
Ro launched as Roman in October 2017 and became Ro in September 2018. It started with an online men's sexual-health service and grew into a direct-to-patient pharmacy.
It raised a $500M Series D at a $5B valuation in March 2021, led by General Catalyst, FirstMark and TQ Ventures.
The company moved into GLP-1 obesity treatment in 2023. In January 2026 it launched the Wegovy pill with Novo Nordisk.